Koppel C J, Driesen B W, de Winter R J, van den Bosch A E, van Kimmenade R, Wagenaar L J, Jukema J W, Hazekamp M G, van der Kley F, Jongbloed M R M, Kiès P, Egorova A D, Verheijen D B H, Damman P, Schoof P H, Wilschut J, Stoel M, Speekenbrink R G H, Voskuil M, Vliegen H W
Department of Cardiology, CAHAL, Centre for Congenital Heart Disease Amsterdam-Leiden, Leiden University Medical Centre, Leiden, The Netherlands.
Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Neth Heart J. 2021 Jun;29(6):311-317. doi: 10.1007/s12471-021-01556-9. Epub 2021 Mar 8.
Current guidelines on coronary anomalies are primarily based on expert consensus and a limited number of trials. A gold standard for diagnosis and a consensus on the treatment strategy in this patient group are lacking, especially for patients with an anomalous origin of a coronary artery from the opposite sinus of Valsalva (ACAOS) with an interarterial course.
To provide evidence-substantiated recommendations for diagnostic work-up, treatment and follow-up of patients with anomalous coronary arteries.
A clinical care pathway for patients with ACAOS was established by six Dutch centres. Prospectively included patients undergo work-up according to protocol using computed tomography (CT) angiography, ischaemia detection, echocardiography and coronary angiography with intracoronary measurements to assess anatomical and physiological characteristics of the ACAOS. Surgical and functional follow-up results are evaluated by CT angiography, ischaemia detection and a quality-of-life questionnaire. Patient inclusion for the first multicentre study on coronary anomalies in the Netherlands started in 2020 and will continue for at least 3 years with a minimum of 2 years of follow-up. For patients with a right or left coronary artery originating from the pulmonary artery and coronary arteriovenous fistulas a registry is maintained.
Primary outcomes are: (cardiac) death, myocardial ischaemia attributable to the ACAOS, re-intervention after surgery and intervention after initially conservative treatment. The influence of work-up examinations on treatment choice is also evaluated.
Structural evidence for the appropriate management of patients with coronary anomalies, especially (interarterial) ACAOS, is lacking. By means of a structured care pathway in a multicentre setting, we aim to provide an evidence-based strategy for the diagnostic evaluation and treatment of this patient group.
当前关于冠状动脉异常的指南主要基于专家共识和有限数量的试验。在这一患者群体中,缺乏诊断的金标准和治疗策略的共识,尤其是对于那些冠状动脉起源于对侧瓦尔萨尔瓦窦(ACAOS)且走行于动脉间的患者。
为冠状动脉异常患者的诊断检查、治疗及随访提供有充分证据支持的建议。
六个荷兰中心为ACAOS患者建立了临床护理路径。前瞻性纳入的患者按照方案接受检查,使用计算机断层扫描(CT)血管造影、缺血检测、超声心动图以及冠状动脉造影并进行冠状动脉内测量,以评估ACAOS的解剖和生理特征。通过CT血管造影、缺血检测和生活质量问卷评估手术和功能随访结果。荷兰首个关于冠状动脉异常的多中心研究于2020年开始纳入患者,并将持续至少3年,随访时间至少2年。对于冠状动脉起源于肺动脉及冠状动脉动静脉瘘的患者,维持一个登记系统。
主要结局包括:(心脏)死亡、由ACAOS导致的心肌缺血、术后再次干预以及初始保守治疗后的干预。还评估了检查对治疗选择的影响。
缺乏关于冠状动脉异常患者,尤其是(动脉间)ACAOS患者适当管理的结构化证据。通过多中心环境下的结构化护理路径,我们旨在为该患者群体的诊断评估和治疗提供基于证据的策略。